52 related articles for article (PubMed ID: 10928046)
1. In vitro PET evaluations in lung cancer cell lines.
Xing T; Wu F; Brodin O; Fasth KJ; Långström B; Bergström M
Anticancer Res; 2000; 20(3A):1375-80. PubMed ID: 10928046
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of [76Br]bromofluorodeoxyuridine and its validation with regard to uptake, DNA incorporation, and excretion modulation in rats.
Lu L; Bergström M; Fasth KJ; Langström B
J Nucl Med; 2000 Oct; 41(10):1746-52. PubMed ID: 11038007
[TBL] [Abstract][Full Text] [Related]
3. In vitro and animal validation of bromine-76-bromodeoxyuridine as a proliferation marker.
Bergström M; Lu L; Fasth KJ; Wu F; Bergström-Pettermann E; Tolmachev V; Hedberg E; Cheng A; Långström B
J Nucl Med; 1998 Jul; 39(7):1273-9. PubMed ID: 9669410
[TBL] [Abstract][Full Text] [Related]
4. Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives.
Nestle U; Kremp S; Grosu AL
Radiother Oncol; 2006 Nov; 81(2):209-25. PubMed ID: 17064802
[TBL] [Abstract][Full Text] [Related]
5. FDG-PET imaging for lymph node staging and pathologic tumor response after neoadjuvant treatment of non-small cell lung cancer.
Ohtsuka T; Nomori H; Ebihara A; Watanabe K; Kaji M; Naruke T; Suemasu K; Uno K
Ann Thorac Cardiovasc Surg; 2006 Apr; 12(2):89-94. PubMed ID: 16702929
[TBL] [Abstract][Full Text] [Related]
6. Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study.
Kaira K; Oriuchi N; Otani Y; Shimizu K; Tanaka S; Imai H; Yanagitani N; Sunaga N; Hisada T; Ishizuka T; Dobashi K; Kanai Y; Endou H; Nakajima T; Endo K; Mori M
Clin Cancer Res; 2007 Nov; 13(21):6369-78. PubMed ID: 17975149
[TBL] [Abstract][Full Text] [Related]
7. 18F-fluoro-2-deoxy-D-glucose standardized uptake value in cavitating non-small-cell lung carcinoma.
Coffey JP; Hill JC
Nucl Med Commun; 2008 Dec; 29(12):1040-5. PubMed ID: 18987523
[TBL] [Abstract][Full Text] [Related]
8. Effect of 6-diazo-5-oxo-L-norleucine (DON) on human carcinoid tumor cell aggregates.
Wu F; Bergström M; Stridsberg M; Orlefors H; Eriksson B; Oberg K; Watanabe Y; Långstrom B
Anticancer Res; 1997; 17(4A):2363-7. PubMed ID: 9252648
[TBL] [Abstract][Full Text] [Related]
9. The distinction of small cell and non-small cell lung cancer by growth in native-state histoculture.
Vescio RA; Connors KM; Bordin GM; Robb JA; Youngkin T; Umbreit JN; Hoffman RM
Cancer Res; 1990 Sep; 50(18):6095-9. PubMed ID: 2168289
[TBL] [Abstract][Full Text] [Related]
10. Expression of the embryonal neural cell adhesion molecule N-CAM in lung carcinoma. Diagnostic usefulness of monoclonal antibody 735 for the distinction between small cell lung cancer and non-small cell lung cancer.
Kibbelaar RE; Moolenaar CE; Michalides RJ; Bitter-Suermann D; Addis BJ; Mooi WJ
J Pathol; 1989 Sep; 159(1):23-8. PubMed ID: 2478684
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations.
Georgiadis MS; Russell EK; Gazdar AF; Johnson BE
Clin Cancer Res; 1997 Mar; 3(3):449-54. PubMed ID: 9815704
[TBL] [Abstract][Full Text] [Related]
12. Effects of dibutyryl cyclic adenosine 3':5'-monophosphate on the growth of cultured human small-cell lung carcinoma and the specific cellular activity of L-dopa decarboxylase.
Francis J; Thompson R; Bernal SD; Luk GD; Baylin SB
Cancer Res; 1983 Feb; 43(2):639-45. PubMed ID: 6293702
[TBL] [Abstract][Full Text] [Related]
13. Phase II study on DON in patients with previously treated advanced lung cancer.
Eagan RT; Frytak S; Nichols WC; Creagan ET; Ingle JN
Cancer Treat Rep; 1982 Aug; 66(8):1665-6. PubMed ID: 6286122
[No Abstract] [Full Text] [Related]
14. Activities of L-dopa decarboxylase and diamine oxidase (histaminase) in human lung cancers and decarboxylase as a marker for small (oat) cell cancer in cell culture.
Baylin SB; Abeloff MD; Goodwin G; Carney DN; Gazdar AF
Cancer Res; 1980 Jun; 40(6):1990-4. PubMed ID: 6245807
[TBL] [Abstract][Full Text] [Related]
15. Relationship between histologic type of primary lung cancer and carbon-11-L-methionine uptake with positron emission tomography.
Fujiwara T; Matsuzawa T; Kubota K; Abe Y; Itoh M; Fukuda H; Hatazawa J; Yoshioka S; Yamaguchi K; Ito K
J Nucl Med; 1989 Jan; 30(1):33-7. PubMed ID: 2536082
[TBL] [Abstract][Full Text] [Related]
16. Uptake of 14C- and 11C-labeled glutamate, glutamine and aspartate in vitro and in vivo.
Wu F; Orlefors H; Bergström M; Antoni G; Omura H; Eriksson B; Watanabe Y; Långström B
Anticancer Res; 2000; 20(1A):251-6. PubMed ID: 10769663
[TBL] [Abstract][Full Text] [Related]
17. Overlap of nuclear diameters in lung cancer cells.
Lee TK; Silverman JF; Horner RD; Scarantino CW
Anal Quant Cytol Histol; 1990 Aug; 12(4):275-8. PubMed ID: 2169753
[TBL] [Abstract][Full Text] [Related]
18. Uptake of glutamine antimetabolites 6-diazo-5-oxo-L-norleucine (DON) and acivicin in sensitive and resistant tumor cell lines.
Huber KR; Rosenfeld H; Roberts J
Int J Cancer; 1988 May; 41(5):752-5. PubMed ID: 3366493
[TBL] [Abstract][Full Text] [Related]
19. A mechanism behind the antitumour effect of 6-diazo-5-oxo-L-norleucine (DON): disruption of mitochondria.
Wu F; Lukinius A; Bergström M; Eriksson B; Watanabe Y; Långström B
Eur J Cancer; 1999 Jul; 35(7):1155-61. PubMed ID: 10533463
[TBL] [Abstract][Full Text] [Related]
20. Use of 5-[(76)Br]bromo-2'-fluoro-2'-deoxyuridine as a ligand for tumour proliferation: validation in an animal tumour model.
Borbath I; Grégoire V; Bergström M; Laryea D; Långström B; Pauwels S
Eur J Nucl Med Mol Imaging; 2002 Jan; 29(1):19-27. PubMed ID: 11807603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
